TTM Nursing TIP Sheet	January 2020
·	

Ordered Target Temperature	
Date/Time Target Temperature Reached	[Goal to Reach Target within 4 hours]
Date/Time to have Continuous EEG in place	[Goal within 6-12 hours of initiation of TTM]
Date/Time to start Rewarming Phase	[Rewarm goal temp is 37°C]
NOTE: if patients has a second cardiac arrest during TTM- restart the 24-hour clock	

	Yes/ No	Was the new Penn Chart Post Cardiac Arrest TTM Orderset Used?
ling	Yes / No	Was Cardiology Consulted? Is patient a candidate for early revascularization?
	Yes/ No	If yes to above question, can cooling be started before transferring patient to the cath lab?
8	,	Head CT completed
Ö		EKG completed
Pre- Cooling		Echocardiogram completed
		Chest X-ray completed
	Yes/ No	Neurology Consult
	Yes/ No	Any other specialty consult needed ? (OB-GYN if pregnant)
-	,	Assess and treat initial Pain (BPS), and Agitation (RASS)
		Initial Labs: ABG with iCA, Mg, CBC/PT/PTT/INR, Fibrinogen, Chem 7, Phos, Lactate, CPK-MB,
i ii		CK, Troponin, Cortisol as indicated, Amylase, Lipase, LFTs, Beta HCG on all women of child
		bearing age, Co-oximetry
Initiation of Cooling		Repeat for 24 hrs only: CPK-MB/CK/Troponin q 6 hrs for 24 hrs
g		Place cooling device, program to target temperature
no	Yes/ No	Is patient a candidate for chilled NSS or LR bolus?
ati	,	Add "hypothermia management" and "bath temp" rows to assessment flowsheet
<u>i</u> E		Add "BSAS" (bedside shivering assessment scale) to vital signs flowsheet, document every 30
=		minutes until at target temperature, then hourly
		Expect decreased insulin secretion and sensitivity – Follow insulin infusion protocol
		Option 1: Early Continuous NMBA
		☐ TO4- Goal 1-2 twitches out of 4
lan 2		☐ BIS (unit based) — Goal 40-60
ng t P or		☐ Sedative infusion
erii 1		☐ Opioid infusion
Shivering Management P Option 1 or		☐ Corneal protection
Sh Bg		· ·
o and		Option 2: Step-Wise Shivering Management based on BSAS. Follow algorithm contained in
Σ		UPHS guideline (see next page). Individual orders are obtained as needed based on shivering
		status.
		Program external cooling device to warm at rate of 0.33 °C per hour to a set goal
ing		temperature of 37° C. / If internal cooling device used set to 0.30 °C per hour
[Discontinue all K+ containing fluids
Rewarm		Check glucose within 30 minutes prior to rewarming, then q 1hour following insulin protocol
\se		Check K+ 2 hours after rewarming phase started
Щ		If continuous NMBA agent infusing, STOP when patient at 36.5 °C
TIPS		Check BPS and RASS q 4 hours, PRN, and with all titration changes
		Neuro Checks q 2 hours and PRN
		Maintain Normothermia for 72 hours after rewarming phase; Keep cooling device in place
		for at least 48 hours after rewarming and re-evaluate
		Serial Labs q 6 hours: Lactate, Chem 7, iCa/Mg/Phos/ABG, CBC and daily PT/PTT/INR

0			
	Shivering Pathway- Step Wise Approach		
Step 0	Initiate standard nursing preventive measures at induction of TTM		
	☐ Assess BSAS q 30 minutes until target temperature achieved, then q hour and PRN		
If BSAS >1	☐ Surface counter warming measures, socks to hands and feet, blanket around head		
proceed to	acetaminophen- Do not administer to patients in fulminant hepatic failure		
Step 1	☐ 650mg liquid via enterally q 4 hours for patients WITHOUT hepatic impairment.		
	☐ 650 mg liquid via enterally every 8 hours not to exceed 2 grams per day for patients with chronic		
	liver disease of acute liver injury		
	buspirone		
	□ 30 mg enterally every 8 hours		
	magnesium		
	☐ Consider maintaining a higher target serum Mg level of 3.0-4.0 mg/dL		
Step 1a	Fentanyl		
	□ IV Fentanyl boluses 12.5-25 mcg every 5 minutes for 2 doses. If after 15 minutes the patient		
	continues to have BSAS ≥ 1, proceed to starting a continuous Fentanyl infusion at 25 mcg/hr, or		
	increasing the infusion rate for patients already on a Fentanyl infusion. If BSAS > 1 after another		
	20-30 minutes, proceed to Step 2		
Step 1b	Meperidine: Meperidine is the preferred agent in patients <u>WITHOUT</u> renal failure		
010p 13	Warning: Meperidine Should not be given at all in late term pregnancy or for prolonged use at any time.		
	Concurrent use of Meperidine with SSRIs or SNRIs may cause serotonin syndrome.		
If BSAS > 1			
proceed to	☐ IV Meperidine boluses 12.5 mg every 5 minutes for 2 doses: may administer 12.5 mg IV every 4-6		
Step 2	hours PRN. Maximum 100mg/24 hours. Contraindicated in renal failure, oliguria, and in patients on		
	MAO inhibitors. IF BSAS > 1 within 30 minutes of bolus dose, go to Step 2		
Step 2	Propofol OR benzodiazepine (if no contraindications, propofol is considered first line)		
	☐ Initiate continuous Propofol infusion (maximum 80 mcg/kg/min as tolerated), or up titrate in		
	patients already on Propofol infusion		
	If BSAS ≥1 despite maximizing highest tolerated dose of continuous Propofol infusion add NMBA		
	bolus in Step 3		
	Bolus dose of midazolam or lorazepam		
	If BSAS > 1 after 5 minutes of bolus, start a continuous infusion at the rate of the initial bolus dose and add the use of NMBA in Step 3		
Step 3	Cisatracurium OR Vecuronium NMBA bolus		
Step 3	☐ Cisatracurium 0.1mg/kg IV bolus every 60 minutes for 2 doses		
	☐ Vecuronium 0.1 mg/kg boluses every 60 minutes for 2 doses		
	Tecare and in the polases every so minutes for 2 doses		
	Note: As the patient becomes hypothermic, the duration of neuromuscular blocking agent becomes		
	prolonged. Monitor BSAS every 1 hour to determine the need for additional doses while cooling to target		
	temperature. If BSAS > 1 after 2 boluses, proceed to Step 4, a continuous NMBA infusio		
Step 4	Cisatracurium OR Vecuronium NMBA Continuous Infusion		
	☐ Cisatricurium continuous infusion starting dose of 1 mcg/kg/min		
	□ Vecuronium continuous infusion starting at 0.4 mcg/kg/m		

^{*}Table taken directly from the UPHS Post Cardiac Arrest Targeted Temperature Management Guideline which can be found on Penn Pathways under critical care.